- Home
- ONDS vs CDTX Comparison
ONDS vs CDTX Comparison
Compare ONDS & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONDS | CDTX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ONDS | CDTX |
|---|---|---|
| Price | $8.46 | $219.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $9.60 | ★ $128.75 |
| AVG Volume (30 Days) | ★ 118.3M | 2.3M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,748,922.00 | N/A |
| Revenue This Year | $406.15 | N/A |
| Revenue Next Year | $219.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 208.40 | N/A |
| 52 Week Low | $0.57 | $15.22 |
| 52 Week High | $11.70 | $221.20 |
Technical Indicators
Market Signals| Indicator | ONDS | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 86.92 |
| Support Level | $7.32 | $219.76 |
| Resistance Level | $9.86 | $220.92 |
| Average True Range (ATR) | 1.07 | 0.83 |
| MACD | 0.13 | -3.22 |
| Stochastic Oscillator | 62.74 | 44.87 |
Price Performance
Historical ComparisonAbout ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.